Can Evista (Raloxifene) Be Used After Mastectomy and 5 Years of Aromatase Inhibitor Therapy?
The use of Evista (raloxifene) after completing 5 years of aromatase inhibitor therapy in a patient with a history of breast cancer and mastectomy is not well-established and raises significant concerns about efficacy and safety. The available evidence suggests this approach should be avoided in favor of better-studied alternatives.
Key Concerns with Sequential Therapy
Animal model data suggest potential interference with raloxifene efficacy in patients who previously completed endocrine therapy, particularly tamoxifen 1. While these studies specifically examined tamoxifen-to-raloxifene sequencing, the concern extends to aromatase inhibitor-to-raloxifene transitions. The guidelines explicitly state: "questions also exist regarding the safety and efficacy of administering tamoxifen to patients who previously took raloxifene" 1, highlighting bidirectional concerns about SERM sequencing after other endocrine therapies.
Raloxifene's Approved Indications
Raloxifene is FDA-approved for risk reduction in women WITHOUT a history of breast cancer 2. The drug label specifically states it is for "postmenopausal women at increased risk for breast cancer" to lower their chance of getting invasive breast cancer—not for secondary prevention after diagnosis 2. The ASCO guidelines consistently describe raloxifene for "women who were not previously diagnosed with breast cancer" 3, 4.
Evidence Gaps in Your Clinical Scenario
The major clinical trials (MORE, CORE, RUTH, STAR) that established raloxifene's efficacy specifically excluded women with a history of breast cancer 3, 2. One observational study found that among 17,968 women with breast cancer history, only 711 (4.0%) received raloxifene, and this use was "largely restricted to women whose initial breast cancer had not been treated with adjuvant tamoxifen or who had received less than 5 years of tamoxifen therapy" 5. This suggests even in clinical practice, sequential use after completing endocrine therapy is uncommon and not well-supported.
What Should Be Done Instead
For a postmenopausal patient who has completed 5 years of aromatase inhibitor therapy:
Extended Aromatase Inhibitor Therapy
Consider extending aromatase inhibitor therapy beyond 5 years (up to 10 years total) for patients with high-risk features 6, 7. The NCCN guidelines specifically recommend this for patients with lymph node involvement 6. The AERAS trial demonstrated that continuing anastrozole for an additional 5 years improved disease-free survival (91% vs 86%, HR 0.61, P<0.001) 7.
If Osteoporosis is the Primary Concern
If the motivation for considering raloxifene is osteoporosis management rather than breast cancer risk reduction:
- Use bisphosphonates or denosumab for bone health 8, 6
- These agents are specifically recommended for postmenopausal patients receiving aromatase inhibitor therapy 6
- They address bone density without the uncertainty of raloxifene's efficacy in this setting
Contraindications to Consider
The patient must not have 9, 2:
- History of deep vein thrombosis, pulmonary embolism, or stroke
- Known inherited clotting disorders
- Anticipated prolonged immobilization or surgery
Clinical Bottom Line
Do not use raloxifene after completing aromatase inhibitor therapy for breast cancer. Instead, either extend aromatase inhibitor therapy (if high-risk features present) or use bone-specific agents if osteoporosis is the concern. The lack of evidence supporting raloxifene's efficacy in women with prior breast cancer, combined with concerns about sequential endocrine therapy interference, makes this an inappropriate choice 1, 5.